Management of patients with uterine bleeding during menopausal hormone therapy
https://doi.org/10.51793/OS.2021.24.3.006
Abstract
The trends in life expectancy that have been observed in recent decades directly affect the activities of an obstetrician-gynecologist due to the fact that women need not only to live a long life, but also to reduce the number of diseases, the development of which is often associated with the onset of the menopausal transition and postmenopause. The task of doctors is to help patients to enter the postmenopausal period as gently as possible, minimizing the manifestations of the climacteric syndrome. Currently, the most effective method of treating early climacteric symptoms is menopausal hormone therapy. The article discusses modern approaches to the conduct of menopausal hormone therapy in the event of menopausal disorders, approaches to the selection of menopausal hormone therapy, taking into account the characteristics of each individual patient. The therapeutic effects and possibilities of menopausal hormone therapy, the problems of its acceptability, as well as the management of postmenopausal patients with uterine bleeding are considered.
About the Authors
A. Z. Khashukoeva
N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
M. V. Burdenko
N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
A. V. Overko
N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
T. E. Ryzhova
Russian Clinical and Research Center of Gerontology N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
M. S. Safonina
N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Perlman et al. The etiology of menopause: not just ovarian dysfunction but also a role for the central nervous system // Global Reproductive Health. 2018; 3: e08.
2. Gartoulla P., Bell R. J., Worsley R., Davis S. R. Menopausal vasomotor symptoms are associated with poor self-assessed work ability // Maturitas. 2016; 87: 33-39.
3. Griffiths A., Ceausu I., Depypere H. et al. EMAS recommendations for conditions in the workplace for menopausal women // Maturitas. 2016; 85: 79-81
4. Юренева С. В. Современные подходы к коррекции менопаузальных расстройств. М.: ГЭОТАР-Медиа, 2019. 88 с. [Yureneva S. V. Sovremennyye podkhody k korrektsii menopauzal'nykh rasstroystv. [Modern approaches to the correction of menopausal disorders.] M.: GEOTAR-Media, 2019. P. 88.]
5. Muka T., Oliver-Williams C., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R., Kavousi M., Franco O. H. Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis // PLoS One. 2016; 11 (6): e0157417. DOI: 10.1371/journal.pone.0157417. eCollection 2016.
6. Хамошина М. Б., Бриль Ю. А. Менопаузальные расстройства: вариативность терапевтических подходов. М.: Редакция журнала StatusPraesens, 2014. 20 с. [Khamoshina M. B., Bril' Yu. A. Menopauzal'nyye rasstroystva: variativnost' terapevticheskikh podkhodov. [Menopausal disorders: variability of therapeutic approaches] M.: Redaktsiya zhurnala StatusPraesens, 2014. P. 20.]
7. Park S. K., Harlow S. D., Zheng H., et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes // Diabet. Med. 2017; 34: 531-538.
8. Gray K. E., Katon J. G., LeBlanc E. S., et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? // Menopause. 2018; 25 (5): 520-530.
9. Baber R. J., et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy // Climacteric. 2016; 19: 109-150.
10. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society // Menopause. 2017; 24: 728-753.
11. Anagnostis P. et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide // Maturitas. 2020; 135: 82-88. DOI: 10.1016/j.maturitas.2020.03.007. Epub 2020 Mar 16. PMID: 32209279.
12. Slopien R., et al. Menopause and diabetes: EMAS clinical guide // Maturitas. 2018; 117: 6-10.
13. Informed Health Online. Institute for Quality and Efficiency in Health Care (IQWiG). 2006. www.ncbi.nlm.nih.gov/books/NBK279309/?report=printable. Accessed April 3, 2019.
14. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии // ОРГЗДРАВ. 2020, 4. [Otsenka demograficheskogo, sotsial'nogo i ekonomicheskogo effekta pri priyeme menopauzal'noy gormonal'noy terapii [Assessment of the demographic, social and economic effect of taking menopausal hormone therapy] // ORGZDRAV. 2020, 4.]
15. Anagnostis P., Bitzer J., Cano A., et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide // Maturitas. 2020; 135: 82-88.
16. Зайдиева Я. З. Маточные кровотечения в климактерии на фоне заместительной гормональной терапии: эффект прогестогенов // Российский вестник акушера-гинеколога. 2013; 13 (5): 28-31. [Zaydiyeva YA. Z. Matochnyye krovotecheniya v klimakterii na fone zamestitel'noy gormonal'noy terapii: effekt progestogenov [Uterine bleeding in menopause against the background of hormone replacement therapy: the effect of progestogens] // Rossiyskiy vestnik akushera-ginekologa. 2013; 13 (5): 28-31.]
17. Татарова Н. А., Айрапетян М. С., Жигалова Е. В. Стартовая терапия климактерического синдрома переходного менопаузального периода // РМЖ. 2017; 2: 98-103. [Tatarova N. A., Ayrapetyan M. S., Zhigalova Ye. V. Startovaya terapiya klimaktericheskogo sindroma perekhodnogo menopauzal'nogo perioda [Initial therapy of climacteric syndrome of the transitional menopausal period] // RMJ. 2017; 2: 98-103.]
18. Зайдиева Я. З. Альтернативная терапия менопаузальных расстройств у женщин в климактерии // РМЖ. Мать и дитя. 2017; 12: 873-878. [Zaydiyeva Ya. Z. Al'ternativnaya terapiya menopauzal'nykh rasstroystv u zhenshchin v klimakterii [Alternative therapy of menopausal disorders in women in menopause] // RMJ. Mat' i ditya. 2017; 12: 873-878.]
19. Клинические рекомендации (протокол лечения) «Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте» (утв. президентом Российского общества акушеров-гинекологов). М., 2018. 40 с. [Klinicheskiye rekomendatsii (protokol lecheniya) «Menopauzal'naya gormonoterapiya i sokhraneniye zdorov'ya zhenshchin v zrelom vozraste» (utv. prezidentom Rossiyskogo obshchestva akusherov-ginekologov). [Clinical guidelines (treatment protocol) «Menopausal hormone therapy and maintaining the health of women in adulthood» (approved by the President of the Russian Society of Obstetricians and Gynecologists)] M., 2018. P. 40.]
20. Cutimanco-Pacheco V., Arriola-Montenegro J., Mezones-Holguin E., NiñoGarcia R., Bonifacio-Morales N., Lucchetti-Rodríguez A., Ticona-Chávez E., Blümel J. E., Pérez-López F. R., Chedraui P. Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women // Climacteric. 2020; 23 (3).
21. Yang Z., Hu Y., Zhang J., Xu L., Zeng R., Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis // Gynecol Endocrinol. 2017; 33 (2): 87-92.
22. Gompel A., Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment // Climacteric. 2018; 21 (4): 326-332.
23. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases // Br. Med. J. 2019; 364: k4810.
24. Sjögren L. L., Mørch L. S., Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review // Maturitas. 2016; 91: 25-35.
25. Yang Z., Hu Y., Zhang J., Xu L., Zeng R., Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis // Gynecol Endocrinol. 2017; 33 (2): 87-92.
26. Карева Е. Н. Тромбозы и гестагены // Доктор.Ру. 2019; 7 (162): 57-64. DOI: 10.31550/1727-2378-2019-162-7-57-64. [Kareva E. N. Trombozy i gestageny [Thrombosis and gestagens] // Doktor.Ru 2019; 7 (162): 57-64. DOI: 10.31550/1727-2378-2019-162-7-57-64.]
27. Tsiligiannis S. et al. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms // Maturitas. 2020.
Review
For citations:
Khashukoeva A.Z., Burdenko M.V., Overko A.V., Ryzhova T.E., Safonina M.S. Management of patients with uterine bleeding during menopausal hormone therapy. Lechaschi Vrach. 2021;(3):29-34. (In Russ.) https://doi.org/10.51793/OS.2021.24.3.006
Views:
337
JATS XML
Email this article 
